Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Which PD-1 inhibitor will you use with chemotherapy in initial treatment of patients with metastatic anal cancer?
Will you use retifanlimab given benefit in the POD1UM-303/InterAACT-2 trial or presume equivalence and utilize nivolumab or pembrolizumab?